Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?

    loading  Checking for direct PDF access through Ovid

Abstract

Cardiovascular (CV) risk remains in some patients who are treated with statins. Evidence supports a role for triglycerides (TGs) in CV disease. TG-lowering agent outcomes studies have been inconsistent, but eicosapentaenoic acid significantly reduced coronary events in hypercholesterolemic patients who were treated with statins. Ongoing outcomes studies will clarify the role of TG-lowering treatments in CV risk reduction.

Related Topics

    loading  Loading Related Articles